Please ensure Javascript is enabled for purposes of website accessibility

What Investors Didn't Like About Co-Diagnostics' Q4 Update

By Keith Speights - Mar 26, 2021 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company missed earnings expectations and hinted at slowing growth in 2021.

No one expected Co-Diagnostics (CODX 1.22%) to follow up its fantastic gain of nearly 940% in 2020 with anything close to that level this year. However, the molecular-diagnostics stock got off to a great start. The momentum is losing steam now, though.

Co-Diagnostics announced its fourth-quarter and full-year 2020 results after the market close on Thursday. The healthcare stock sank 8% in after-hours trading. Here are the highlights from the company's Q4 update.

COVID-19 Test test tube in gloved hands with person receiving the test in faded background.

Image source: Getty Images.

By the numbers

Co-Diagnostics reported revenue in the fourth quarter of $27.1 million, up 24% quarter over quarter. This result topped the average analyst revenue estimate of nearly $25 million.

The company announced Q4 net income of $12.8 million, or $0.43 per diluted share. This was lower than its Q3 earnings of $15.7 million, or $0.53 per diluted share. It also fell short of the consensus analyst estimate of earnings of $0.48 per share.

Co-Diagnostics ended the fourth quarter with cash, cash equivalents, and marketable securities totaling $47.3 million. 

Behind the numbers

One product generated most of Co-Diagnostics' revenue growth in Q4: The Logix Smart COVID-19 Test. The company received Emergency Use Authorization (EUA) for the test in April 2020. It's been a fun ride for Co-Diagnostics, for the most part, since then.

The problem for the company in the fourth quarter wasn't due to revenue challenges. Co-Diagnostics' spending increased significantly more than its revenue did. In the third quarter, the molecular-diagnostics company's operating expenses totaled nearly $4 million. Co-Diagnostics' operating expenses in Q4 jumped 70% higher to $6.8 million.

However, the company's gross profit margin increased quite a bit. In the fourth quarter, its gross profit margin stood at 84%, up from 73% in the previous quarter.

Looking ahead

What will 2021 look like for Co-Diagnostics? CEO Dwight Egan tried to manage expectations saying that, "COVID-19 test sales may not be as robust as in 2020." However, the company thinks that demand will continue for its COVID-19 tests and other products over the long run.

The company hopes to win an additional EUA for its Logix Smart direct saliva test. It also could benefit if new coronavirus variants spread, boosting demand for COVID-19 testing.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
$4.97 (1.22%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.